Literature DB >> 11880114

Influence of mycophenolic acid on inosine 5'-monophosphate dehydrogenase activity in human peripheral blood mononuclear cells.

Heide Daxecker1, Markus Raab, Mathias M Müller.   

Abstract

BACKGROUND: Inosine 5'-monophosphate dehydrogenase (IMPDH) catalyses the oxidation of inosine 5'-monophosphate (IMP) to xanthosine 5'-monophosphate (XMP). Thus, this enzyme plays an important role in the rate-limiting step of the de novo guanine nucleotide biosynthesis, making it a potent target for immunosuppressive drugs. Mycophenolic acid (MPA) is the most potent and specific inhibitor of IMPDH.
METHOD: IMPDH activity is determined via evaluation of XMP formation and the inhibitory influence of MPA in human peripheral blood mononuclear cells (PBMCs) is assessed by means of high-performance liquid chromatography (HPLC). For this objective, we have optimised a method based on solvent-generated ion exchange chromatography by cautiously varying mobile phase parameters.
RESULTS: The optimised method renders it possible to separate 18 analytes in 54 min in a single isocratic experiment and to measure the IMPDH activity in the lysate of human PBMCs in dependence on incubation time, substrate, co-substrate and inhibitor concentrations. In this way, we have determined the Michaelis-Menten constants K(M) and V(max) for IMP and beta-NAD+ and the inhibitor constant K(i) for MPA.
CONCLUSIONS: The chromatographic method presented in this report allows a rapid, reliable and reproducible quantification of IMPDH activity in PBMCs and therefore represents an attractive tool for the pharmacodynamic monitoring of the effects of MPA in patients under immunosuppressive therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11880114     DOI: 10.1016/s0009-8981(01)00801-4

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  6 in total

1.  Recipient pretransplant inosine monophosphate dehydrogenase activity in nonmyeloablative hematopoietic cell transplantation.

Authors:  Meagan J Bemer; Linda J Risler; Brian R Phillips; Joanne Wang; Barry E Storer; Brenda M Sandmaier; Haichuan Duan; Brianne S Raccor; Michael J Boeckh; Jeannine S McCune
Journal:  Biol Blood Marrow Transplant       Date:  2014-06-09       Impact factor: 5.742

2.  A pilot pharmacologic biomarker study in HLA-haploidentical hematopoietic cell transplant recipients.

Authors:  Meagan J Bemer; Mohamed Sorror; Brenda M Sandmaier; Paul V O'Donnell; Jeannine S McCune
Journal:  Cancer Chemother Pharmacol       Date:  2013-08-02       Impact factor: 3.333

3.  Pharmacokinetic and pharmacodynamic analysis of inosine monophosphate dehydrogenase activity in hematopoietic cell transplantation recipients treated with mycophenolate mofetil.

Authors:  Hong Li; Donald E Mager; Brenda M Sandmaier; Barry E Storer; Michael J Boeckh; Meagan J Bemer; Brian R Phillips; Linda J Risler; Jeannine S McCune
Journal:  Biol Blood Marrow Transplant       Date:  2014-04-13       Impact factor: 5.742

4.  Inosine monophosphate dehydrogenase expression and activity are significantly lower in kidney transplant recipients with diabetes mellitus.

Authors:  Miroslav Dostalek; Reginald Y Gohh; Fatemeh Akhlaghi
Journal:  Ther Drug Monit       Date:  2013-06       Impact factor: 3.681

5.  Effect of diabetes mellitus on mycophenolate sodium pharmacokinetics and inosine monophosphate dehydrogenase activity in stable kidney transplant recipients.

Authors:  Chirag G Patel; Katherine Richman; Dongfang Yang; Bingfang Yan; Reginald Y Gohh; Fatemeh Akhlaghi
Journal:  Ther Drug Monit       Date:  2007-12       Impact factor: 3.681

6.  Proteomic and systems biology analysis of monocytes exposed to securinine, a GABA(A) receptor antagonist and immune adjuvant.

Authors:  Matt Shipman; Kirk Lubick; David Fouchard; Rajani Guram; Paul Grieco; Mark Jutila; Edward A Dratz
Journal:  PLoS One       Date:  2012-09-13       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.